Despite the advent of immunotherapy in the treatment of human-papilloma-virus (HPV)-negative head and neck squamous cell carcinoma, the overall prognosis still remains dismal. Novel therapeutic approaches are thus urgently needed. We recently reported that SET and MYND containing 3 (SMYD3), a protein methyltransferase...
Jawad Akhtar, Sai Reddy Doda, William J. Moore et al.· bioRxiv· 0 citations
This work provides rationale for the depletion/degradation of SUV420H1 as a novel therapeutic strategy to hinder proliferation and invasion, and to impart sensitization to anti-PD-1 immunotherapy for patients with HPV-negative HNSCC tumors with SUV420H1 gain/amplification.
A. Moshiri, Marie K. Luff, S. Kim et al.· Cell Death & Disease· 0 citations
Investigating how the vaccine shapes the CD4+ T cell immunity and how these responses cooperate in reducing the acquisition found that DV1 DNA/ALVAC/gp120 vaccine elicited envelope-specific immunomodulatory Tr1 CD4+ T cells, and that total Tr1 responses were associated with a reduced risk of viral acquisition.
Massimiliano Bissa, S. Fourati, Sohyoung Kim et al.· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.